MajorAntiretroviral, HIV protease inhibitor×Antiretroviral, non-nucleoside reverse transcriptase inhibitor (NNRTI)
Updated · Methodology
Mechanism
CYP3A4 is the main enzyme that metabolises atazanavir in the liver (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA, section 5.2). Efavirenz induces CYP3A4, CYP2B6 and the glucuronidation enzyme UGT1A1 in vivo (efavirenz SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5), so atazanavir levels fall. Without a booster, efavirenz 600 mg lowered the area under the concentration–time curve (AUC) of atazanavir 400 mg by 74% and its trough concentration by 93% (atazanavir/cobicistat SmPC, EMA, section 4.5). With atazanavir 400 mg plus ritonavir 100 mg, the AUC did not change. The atazanavir trough, however, was 42% lower than with the usual 300 mg/100 mg regimen without efavirenz, and this may impair its efficacy. With ritonavir 200 mg, the trough did not fall compared with historical data (atazanavir SmPC, EMA, section 4.5). Efavirenz is also expected to lower cobicistat levels, which may then be too low to boost atazanavir adequately (atazanavir/cobicistat SmPC, EMA, sections 4.4 and 4.5).
Symptoms
The documents describe no symptoms specific to this combination. The main risk is lower atazanavir levels. Treatment for human immunodeficiency virus (HIV) may then lose its effect, that is, the virological response, and the virus may become resistant to atazanavir (atazanavir/cobicistat summary of product characteristics, SmPC, European Medicines Agency, EMA, section 4.5; Reyataz prescribing information, US Food and Drug Administration, FDA, section 5.7). If the ritonavir dose is raised to 200 mg for the combination, the safety profile of atazanavir may change, with cardiac effects and higher bilirubin (atazanavir SmPC, EMA, section 4.4). Common adverse effects of the drugs themselves are nausea, diarrhoea and jaundice with atazanavir, and rash, dizziness, nausea, headache and fatigue with efavirenz (atazanavir SmPC, EMA, and efavirenz SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.8).
Management
The European atazanavir SmPCs and the Spanish efavirenz SmPC do not recommend the combination, whether atazanavir is boosted with ritonavir or cobicistat or given unboosted (atazanavir and atazanavir/cobicistat summaries of product characteristics, SmPC, European Medicines Agency, EMA, sections 4.4 and 4.5; efavirenz SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.5). If a non-nucleoside reverse transcriptase inhibitor cannot be avoided, an increase to atazanavir 400 mg and ritonavir 200 mg once daily with efavirenz may be considered, under close clinical monitoring (atazanavir SmPC, EMA, section 4.4; efavirenz SmPC, AEMPS, section 4.5). For people not previously treated for human immunodeficiency virus (HIV), the US labels give atazanavir 400 mg with ritonavir 100 mg once daily with food. Efavirenz 600 mg is taken once daily on an empty stomach, preferably at bedtime. In treatment-experienced patients, the US labels do not recommend the combination (atazanavir and efavirenz prescribing information, US Food and Drug Administration, FDA, section 7). The US label gives no such regimen without ritonavir: with efavirenz, atazanavir is taken with ritonavir 100 mg (Reyataz prescribing information, FDA, sections 2.3 and 7).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- EMA: Ficha técnica: Atazanavir/cobicistat (EU/1/15/1025), sección 4.5 (2026)– EMA, Evotaz 300 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, secciones 4.3 y 4.5
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.3 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 10/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5
- AEMPS: Ficha técnica: Efavirenz (nº registro 79191), sección 4.5 (2025)– AEMPS, CIMA, nº registro 79191 (Efavirenz Aurovitas 600 mg comprimidos recubiertos con película EFG), revisión 04/2025, secciones 4.3, 4.4, 4.5 y 5.2; la autorización del original Sustiva (EU/1/99/110) está revocada
- FDA: Efavirenz tablets (Cipla USA) prescribing information (2024)– FDA, DailyMed setid 92603fa5-7a2c-4bfb-9a70-aadb4fba952c (Cipla USA), versión 7 (effective 31.03.2024, publicada 10.09.2024), secciones 5.1, 5.2, 5.9, 7.1 y 7.2; SUSTIVA en DailyMed solo figura con etiqueta de reenvasador de 2013